In the BioHarmony Drug Report Database

"Preview" Icon

Alectinib

Alecensa (alectinib) is a small molecule pharmaceutical. Alectinib was first approved as Alecensa on 2015-12-11. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. The pharmaceutical is active against ALK tyrosine kinase receptor. In addition, it is known to target hepatocyte growth factor receptor. Alecensa’s patent is valid until 2035-04-24 (FDA).

 

Trade Name

 

Alecensa
 

Common Name

 

alectinib
 

ChEMBL ID

 

CHEMBL1738797
 

Indication

 

non-small-cell lung carcinoma
 

Drug Class

 

Tyrosine kinase inhibitors

Image (chem structure or protein)

Alectinib structure rendering